315 related articles for article (PubMed ID: 30937157)
1. Infliximab in inflammatory bowel disease.
Papamichael K; Lin S; Moore M; Papaioannou G; Sattler L; Cheifetz AS
Ther Adv Chronic Dis; 2019; 10():2040622319838443. PubMed ID: 30937157
[TBL] [Abstract][Full Text] [Related]
2. Systematic Review With Meta-Analysis: Anti-TNF Therapy in Refractory Pouchitis and Crohn's Disease-Like Complications of the Pouch After Ileal Pouch-Anal Anastomosis Following Colectomy for Ulcerative Colitis.
Huguet M; Pereira B; Goutte M; Goutorbe F; Dubois A; Bommelaer G; Buisson A
Inflamm Bowel Dis; 2018 Jan; 24(2):261-268. PubMed ID: 29361101
[TBL] [Abstract][Full Text] [Related]
3. Review article: pharmacological aspects of anti-TNF biosimilars in inflammatory bowel diseases.
Papamichael K; Van Stappen T; Jairath V; Gecse K; Khanna R; D'Haens G; Vermeire S; Gils A; Feagan BG; Levesque BG; Vande Casteele N
Aliment Pharmacol Ther; 2015 Nov; 42(10):1158-69. PubMed ID: 26365281
[TBL] [Abstract][Full Text] [Related]
4. Efficacy, Safety and Immunogenicity of Biosimilars in Inflammatory Bowel Diseases: A Systematic Review.
Martelli L; Peyrin-Biroulet L
Curr Med Chem; 2019; 26(2):270-279. PubMed ID: 27758715
[TBL] [Abstract][Full Text] [Related]
5. Pharmacology and metabolism of infliximab biosimilars - A new treatment option in inflammatory bowel diseases.
Włodarczyk M; Fichna J; Sobolewska-Włodarczyk A
Pharmacol Rep; 2016 Aug; 68(4):797-801. PubMed ID: 27162107
[TBL] [Abstract][Full Text] [Related]
6. The Experience with Biosimilars of Infliximab in Inflammatory Bowel Disease.
Avila-Ribeiro P; Fiorino G; Danese S
Curr Pharm Des; 2017; 23(44):6759-6769. PubMed ID: 29205114
[TBL] [Abstract][Full Text] [Related]
7. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
[TBL] [Abstract][Full Text] [Related]
8. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
Magro F; Portela F
BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
[TBL] [Abstract][Full Text] [Related]
9. Systematic review with meta-analysis: the efficacy and safety of CT-P13, a biosimilar of anti-tumour necrosis factor-α agent (infliximab), in inflammatory bowel diseases.
Komaki Y; Yamada A; Komaki F; Micic D; Ido A; Sakuraba A
Aliment Pharmacol Ther; 2017 Apr; 45(8):1043-1057. PubMed ID: 28239873
[TBL] [Abstract][Full Text] [Related]
10. Infliximab Biosimilars in the Treatment of Inflammatory Bowel Diseases: A Systematic Review.
Radin M; Sciascia S; Roccatello D; Cuadrado MJ
BioDrugs; 2017 Feb; 31(1):37-49. PubMed ID: 28035633
[TBL] [Abstract][Full Text] [Related]
11. Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trial.
Strik AS; van de Vrie W; Bloemsaat-Minekus JPJ; Nurmohamed M; Bossuyt PJJ; Bodelier A; Rispens T; van Megen YJB; D'Haens GR;
Lancet Gastroenterol Hepatol; 2018 Jun; 3(6):404-412. PubMed ID: 29606564
[TBL] [Abstract][Full Text] [Related]
12. A SPECIAL MEETING REVIEW EDITION: Highlights in Anti-Tumor Necrosis Factor Monitoring and Antibody Monitoring From the 2014 DDW Meeting: Digestive Disease Week 2014 May 3-6, 2014 • Chicago, Illinois: Special Reporting on:• Therapeutic Monitoring of Anti-TNF Levels and Antibodies to Predict Response and Achieve Mucosal Healing• Prospective Therapeutic Drug Monitoring and Optimization of Infliximab Maintenance Therapy in IBD• Classification of Non-IBD, Crohn's Disease and Ulcerative Colitis in a Young Patient Population Using a Multi-Marker Diagnostic Panel• Persistence of Antibodies to Infliximab for More Than Two Months Predicts Loss of Response to Infliximab in Inflammatory Bowel Diseases• Pre-Operative Serological Markers May Predict Postoperative Crohn's Disease Recurrence: Results From a Prospective Mono-Centric Trial• Antibodies and Levels of Biologies-Reactive vs Proactive Measurements• Higher 6-Thioguanine Nucleotide Concentrations Are Associated With Higher Trough Levels of Infliximab in Patients on Combination Therapy• The Clinical and Immunological Significance of Low Levels of Infliximab in the Absence of Anti-lnfliximab Antibodies in Patients With IBD• Antibodies to Adalimumab Predict Inflammation in Crohn's Patients on Maintenance Adalimumab Therapy• ATG16L1 Genotype Is Associated With Response to Anti-TNFWith Expert Commentary by:William J. Sandborn, MDProfessor and Chief, Division of Gastroenterology Director, UCSD IBD CenterUC San Diego Health SystemLa Jolla, California.
Gastroenterol Hepatol (N Y); 2014 Jul; 10(7 Suppl 4):1-20. PubMed ID: 25892982
[No Abstract] [Full Text] [Related]
13. Progress with infliximab biosimilars for inflammatory bowel disease.
Kurti Z; Gonczi L; Lakatos PL
Expert Opin Biol Ther; 2018 Jun; 18(6):633-640. PubMed ID: 29688797
[TBL] [Abstract][Full Text] [Related]
14. Current, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases.
Amiot A; Peyrin-Biroulet L
Therap Adv Gastroenterol; 2015 Mar; 8(2):66-82. PubMed ID: 25729432
[TBL] [Abstract][Full Text] [Related]
15. Exposure to Anti-tumor Necrosis Factor Medications Increases the Incidence of Pouchitis After Restorative Proctocolectomy in Patients With Ulcerative Colitis.
Bertucci Zoccali M; Hyman NH; Skowron KB; Rubin M; Cannon LM; Hurst RD; Umanskiy K; Rubin DT; Shogan BD
Dis Colon Rectum; 2019 Nov; 62(11):1344-1351. PubMed ID: 31596761
[TBL] [Abstract][Full Text] [Related]
16. Anti-TNF Biosimilars in Inflammatory Bowel Disease: Searching the Proper Patient's Profile.
Danese S; Fiorino G
Curr Med Chem; 2019; 26(2):280-287. PubMed ID: 29756565
[TBL] [Abstract][Full Text] [Related]
17. Infliximab therapy in pediatric Crohn's pouchitis.
Kooros K; Katz AJ
Inflamm Bowel Dis; 2004 Jul; 10(4):417-20. PubMed ID: 15475750
[TBL] [Abstract][Full Text] [Related]
18. Crohn's-like complications in patients with ulcerative colitis after total proctocolectomy and ileal pouch-anal anastomosis.
Goldstein NS; Sanford WW; Bodzin JH
Am J Surg Pathol; 1997 Nov; 21(11):1343-53. PubMed ID: 9351572
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: A retrospective multicenter study.
Jung YS; Park DI; Kim YH; Lee JH; Seo PJ; Cheon JH; Kang HW; Kim JW
J Gastroenterol Hepatol; 2015 Dec; 30(12):1705-12. PubMed ID: 25974251
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of the Biosimilar Infliximab CT-P13 Treatment in Inflammatory Bowel Diseases: A Prospective, Multicentre, Nationwide Cohort.
Gecse KB; Lovász BD; Farkas K; Banai J; Bene L; Gasztonyi B; Golovics PA; Kristóf T; Lakatos L; Csontos ÁA; Juhász M; Nagy F; Palatka K; Papp M; Patai Á; Lakner L; Salamon Á; Szamosi T; Szepes Z; Tóth GT; Vincze Á; Szalay B; Molnár T; Lakatos PL
J Crohns Colitis; 2016 Feb; 10(2):133-40. PubMed ID: 26661272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
